vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and RENAISSANCERE HOLDINGS LTD (RNR). Click either name above to swap in a different company.
RENAISSANCERE HOLDINGS LTD is the larger business by last-quarter revenue ($2.2B vs $1.2B, roughly 1.8× Jazz Pharmaceuticals plc). RENAISSANCERE HOLDINGS LTD runs the higher net margin — 23.5% vs 17.0%, a 6.5% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -36.8%). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs -11.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
RenaissanceRe Holdings Ltd is a Bermudian provider of reinsurance, insurance and other related business services. The company operates in reinsurance, insurance and ventures.
JAZZ vs RNR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.2B |
| Net Profit | $203.5M | $515.8M |
| Gross Margin | — | — |
| Operating Margin | 21.2% | — |
| Net Margin | 17.0% | 23.5% |
| Revenue YoY | 10.1% | -36.8% |
| Net Profit YoY | 6.5% | 72.6% |
| EPS (diluted) | $3.34 | $6.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.2B | ||
| Q4 25 | $1.2B | $3.0B | ||
| Q3 25 | $1.1B | $3.2B | ||
| Q2 25 | $1.0B | $3.2B | ||
| Q1 25 | $897.8M | $3.5B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $1.1B | $4.0B | ||
| Q2 24 | $1.0B | $2.8B |
| Q1 26 | — | $515.8M | ||
| Q4 25 | $203.5M | $760.5M | ||
| Q3 25 | $251.4M | $916.5M | ||
| Q2 25 | $-718.5M | $835.4M | ||
| Q1 25 | $-92.5M | $170.0M | ||
| Q4 24 | $191.1M | $-189.7M | ||
| Q3 24 | $215.1M | $1.2B | ||
| Q2 24 | $168.6M | $503.9M |
| Q1 26 | — | — | ||
| Q4 25 | 21.2% | 42.5% | ||
| Q3 25 | 5.1% | 46.3% | ||
| Q2 25 | -65.6% | 41.8% | ||
| Q1 25 | -6.2% | -2.0% | ||
| Q4 24 | 17.5% | -3.6% | ||
| Q3 24 | 24.7% | 43.7% | ||
| Q2 24 | 19.5% | 25.0% |
| Q1 26 | — | 23.5% | ||
| Q4 25 | 17.0% | 25.6% | ||
| Q3 25 | 22.3% | 28.7% | ||
| Q2 25 | -68.7% | 26.1% | ||
| Q1 25 | -10.3% | 4.9% | ||
| Q4 24 | 17.6% | -8.3% | ||
| Q3 24 | 20.4% | 29.8% | ||
| Q2 24 | 16.5% | 17.8% |
| Q1 26 | — | $6.57 | ||
| Q4 25 | $3.34 | $16.16 | ||
| Q3 25 | $4.08 | $19.40 | ||
| Q2 25 | $-11.74 | $17.20 | ||
| Q1 25 | $-1.52 | $3.27 | ||
| Q4 24 | $2.97 | $-3.76 | ||
| Q3 24 | $3.42 | $22.62 | ||
| Q2 24 | $2.49 | $9.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $1.6B |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $4.3B |
| Total Assets | $11.7B | $53.7B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $2.4B | $1.7B | ||
| Q3 24 | $2.2B | $1.6B | ||
| Q2 24 | $1.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $5.4B | $2.3B | ||
| Q3 25 | $5.4B | $2.2B | ||
| Q2 25 | $5.4B | $2.3B | ||
| Q1 25 | $5.4B | $2.8B | ||
| Q4 24 | $6.1B | $1.9B | ||
| Q3 24 | $6.1B | $1.9B | ||
| Q2 24 | $5.7B | $2.0B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $4.3B | $11.6B | ||
| Q3 25 | $4.0B | $11.5B | ||
| Q2 25 | $3.7B | $10.8B | ||
| Q1 25 | $4.2B | $10.3B | ||
| Q4 24 | $4.1B | $10.6B | ||
| Q3 24 | $4.2B | $11.2B | ||
| Q2 24 | $3.8B | $10.2B |
| Q1 26 | — | $53.7B | ||
| Q4 25 | $11.7B | $53.8B | ||
| Q3 25 | $11.4B | $54.5B | ||
| Q2 25 | $10.9B | $54.7B | ||
| Q1 25 | $11.5B | $53.6B | ||
| Q4 24 | $12.0B | $50.7B | ||
| Q3 24 | $12.3B | $52.8B | ||
| Q2 24 | $11.4B | $51.6B |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | 0.20× | ||
| Q3 25 | 1.35× | 0.19× | ||
| Q2 25 | 1.45× | 0.21× | ||
| Q1 25 | 1.29× | 0.27× | ||
| Q4 24 | 1.49× | 0.18× | ||
| Q3 24 | 1.47× | 0.17× | ||
| Q2 24 | 1.52× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | — |
| Free Cash FlowOCF − Capex | $345.8M | — |
| FCF MarginFCF / Revenue | 28.9% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $362.5M | $483.0M | ||
| Q3 25 | $474.6M | $1.6B | ||
| Q2 25 | $88.9M | $1.5B | ||
| Q1 25 | $429.8M | $157.8M | ||
| Q4 24 | $398.6M | $778.9M | ||
| Q3 24 | $398.7M | $1.5B | ||
| Q2 24 | $331.4M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $345.8M | — | ||
| Q3 25 | $459.4M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | — | ||
| Q4 24 | $385.3M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $324.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 31.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.78× | 0.64× | ||
| Q3 25 | 1.89× | 1.73× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | 1.26× | ||
| Q2 24 | 1.97× | 2.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RNR
Segment breakdown not available.
